Takeda bags Japanese approval for Crohn’s cell therapy AlofiselTakeda has chalked up another milestone for its Alofisel cell therapy for a complication of Crohn’s disease, becoming Share XTakeda bags Japanese approval for Crohn’s cell therapy Alofiselhttps://pharmaphorum.com/news/takeda-bags-japanese-approval-for-crohns-cell-therapy-alofisel/
Incyte leads JAK push into eczema as FDA clears Opzelura creamThe FDA has approved Incyte’s Opzelura cream for atopic dermatitis, commonly called eczema, becoming the first and only Share XIncyte leads JAK push into eczema as FDA clears Opzelura creamhttps://pharmaphorum.com/news/incyte-leads-jak-push-into-eczema-as-fda-clears-opzelura-cream/
FDA clears Seagen, Genmab’s Tivdak ADC for cervical cancerAntibody-drug conjugate (ADC) specialist Seagen has claimed its fourth product approval in the US, getting the nod from Share XFDA clears Seagen, Genmab’s Tivdak ADC for cervical cancerhttps://pharmaphorum.com/news/fda-clears-seagen-genmabs-tivdak-adc-for-cervical-cancer/
FDA OKs first biosimilar of Roche’s blockbuster AMD drug LucentisSamsung Bioepis and Biogen have claimed the first FDA approval for a biosimilar version of Roche and Novartis’ Share XFDA OKs first biosimilar of Roche’s blockbuster AMD drug Lucentishttps://pharmaphorum.com/news/fda-oks-first-biosimilar-of-roches-blockbuster-amd-drug-lucentis/
Takeda gets a win for its Wave1 pipeline, as Exkivity nabs FDA approvalTakeda has had a run of bad luck with its Wave1 pipeline of new drug candidates of late, Share XTakeda gets a win for its Wave1 pipeline, as Exkivity nabs FDA approvalhttps://pharmaphorum.com/news/takeda-gets-a-win-for-its-wave1-pipeline-as-exkivity-nabs-fda-approval/
Pfizer gets first approval, in UK, for Xeljanz follow-up CibinqoPfizer has claimed its first regulatory approval worldwide for Cibinqo, its JAK inhibitor for atopic dermatitis, from the Share XPfizer gets first approval, in UK, for Xeljanz follow-up Cibinqohttps://pharmaphorum.com/news/pfizer-gets-first-approval-in-uk-for-xeljanz-follow-up-cibinqo/
FDA clears J&J’s twice-yearly Invega for schizophreniaOne of the biggest challenges to treating schizophrenia is non-compliance with treatment, but Johnson & Johnson’s pharma unit Share XFDA clears J&J’s twice-yearly Invega for schizophreniahttps://pharmaphorum.com/news/fda-clears-jjs-twice-yearly-invega-for-schizophrenia/
Incyte, MorphoSys’ CAR-T rival tafasitamab approved in EUIncyte and MorphoSys’ antibody therapy tafasitamab has been approved in Europe, promising to provide a more convenient alternative Share XIncyte, MorphoSys’ CAR-T rival tafasitamab approved in EUhttps://pharmaphorum.com/news/incyte-morphosys-car-t-rival-tafasitamab-approved-in-eu/
AbbVie’s Rinvoq cleared in EU for atopic dermatitisThe FDA may be reluctant to trust JAK inhibitors, but the European Commission is more willing, and has Share XAbbVie’s Rinvoq cleared in EU for atopic dermatitishttps://pharmaphorum.com/news/abbvies-rinvoq-is-first-jak-drug-cleared-in-eu-for-atopic-dermatitis/
